The vascular disrupting agents market is projected to be worth USD 2 billion by 2030, growing at an annualized rate of over 60%, claims Roots Analysis

 

Vascular disrupting agents (VDAs) are the novel oncology drugs being developed to more specifically combat complex, life threatening cancer indications

 

London

 

Roots Analysis has announced the addition of “Vascular Disrupting Agents Market, 2021-2030” report to its list of offerings.

 

Despite multiple cancer treatment options, there is an evident unmet need for anti-cancer therapies with better efficacy and less toxicity. The vascular disrupting agents, which target the established tumor vasculature and disrupt blood flow to cancerous tissue, have garnered considerable interest as a novel anticancer therapeutic modality. 

 

To order this 290+ page report, which features 110+ figures and 125+ tables, please visit https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market.html

 

Key Market Insights

 

Currently, more than 120 vascular disrupting agents are in the development pipeline

Around 50% of the vascular disrupting agents are being evaluated in phase II clinical trials, while more than 5% are either marketed or in phase III of development. Examples of phase III drugs include Bavituximab (non-small cell lung cancer), Icaritin (hepatocellular carcinoma), NGR-TNF (malignant pleural mesothelioma), Padeliporfin (transitional cell cancer of renal pelvis and ureter), Plinabulin (non-small cell lung cancer, chemotherapy-induced neutropenia) and VB-111 (glioblastoma, recurrent platinum resistant ovarian cancer). Further, 35% molecules are in phase I trials.

 

Around 30 industry and non-industry players are engaged in the development of vascular disrupting agents

Around 40% of these firms are start-ups / small players (with less than 50 employees). It is also worth highlighting that, majority of the firms engaged in this domain (56%) are based in North America, followed by Asia Pacific (25%) and Europe (19%).

 

Over 530 clinical trials are currently evaluating the therapeutic effects of vascular disrupting agents, worldwide

It is worth mentioning that most of the trials were / are being conducted in North America (56%), where more than 40% of the total number of patients had been enrolled. This is followed by clinical research activity in Europe (24%) and Asia Pacific (20%).

 

Around 800 articles related to vascular disrupting agents have been published in reputed scientific journals, since 2016 

More than 30% of the publications mentioned in the report, were focused on the assessment of treatment safety / effectiveness of various vascular disrupting agents. Popular journals that have published multiple articles related vascular disrupting agents, include Scientific Reports, Oncotarget, European Journal of Medicinal Chemistry, and PLoS One.

 

Close to 220 grants have been awarded to support research on vascular disrupting agents, since 2016

An estimated USD 96 million in grants have been awarded to various companies / organizations working in this domain, during time period between 2016 and January 2021. Almost 20% of the total grant amount was funded by the National Cancer Institute.

 

Over 265 eminent scientists (identified as key opinion leaders (KOLs)) are involved in the clinical trials of vascular disrupting agents

Around 50% of these KOLs are associated with the organizations based in North America, followed by those in Asia Pacific (38%) and Europe (12%). Majority of these KOLs are currently affiliated to hospitals and medical centers.

 

The market is anticipated to grow at a CAGR of over 60%, during the period 2021-2030

Growth in this domain is anticipated to be driven by the drugs that are being developed for the treatment of non-small cell lung cancer. North America (primarily the US) and Europe are expected to capture around 50% of the market share by 2030, in terms of the sales-based revenues.

 

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market/request-sample.html             

 

Key Questions Answered

§  Who are the leading industry and non-industry players in this market?

§  Which cancer indications can be treated with vascular disrupting agents?

§  Which geographies are the most active in conducting clinical trials on vascular disrupting agents?

§  What is the focus area of the research activities going on in this domain?

§  Which are the leading administering institute centers supporting the research related to this domain?

§  Who are the key opinion leaders that can help you drive your development efforts?

§  How is the current and future market opportunity likely to be distributed across key market segments?

 

The USD 2 billion (by 2030) financial opportunity within the vascular disrupting agents market has been analyzed across the following segments:

§  Target Indication

§  Chemotherapy-induced Neutropenia

§  Glioblastoma

§  Hepatocellular Carcinoma

§  Malignant Pleural Mesothelioma

§  Non-Small Cell Lung Cancer

§  Prostate Cancer

§  Recurrent Platinum Resistant Ovarian Cancer

§  Transitional Cell Cancer of Renal Pelvis and Ureter

 

§  Therapeutic Area

§  Solid Tumors

§  Others

 

§  Type of Molecule

§  Small Molecules

§  Ligand Directed Agents

 

§  Type of Therapy

§  Monotherapy

§  Combination Therapy

 

§  Route of Administration

§  Oral

§  Intravenous

 

§  Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific and Rest of the World

 

 

The research includes detailed profiles of key players (listed below), each profile features an overview of the company, its financial information (if available), drug portfolio, details on recent developments, as well as an informed future outlook.

§  AGC Biologics

§  Avid Bioservices

§  Bionomics

§  Iceni Pharmaceuticals

§  Myrexis

§  Oncotelic Therapeutics

§  VBL Therapeutics

 

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market.html

or email sales@rootsanalysis.com

                                                                                                                                               

 

You may also be interested in the following titles:

1.     TIL-based Therapies Market, 2021-2030

2.     TCR-based Therapies Market, 2021-2030

3.     Peptide Therapeutics Market, 2021-2030

 

                       

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Comments

Post a Comment

Popular posts from this blog

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

    Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals   Roots Analysis is pleased to announce the publication of its recent study, titled “ Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 ” report to its list of offerings.   The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the r...
Read more

PRE-INSTALLED SINGLE-USE SENSORS FOR BIOPROCESSING-CASE STUDY

    During our research, we identified 31 pre-installed single-use sensors developed by various companies for bioprocessing. The current market landscape is predominantly characterized by the presence of large (38%) and small (37%) players. Notable examples of large players in this domain include ( in alphabetical order ) Cytiva Life Sciences (US), Hamilton (US) and Pall (US).   To Request Sample Pages -: https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html       Majority of the pre-installed single-use sensor systems are designed for both, research and biomanufacturing purposes. This is followed by those designed for only research purposes. Notable examples of products which are developed for both research and biomanufacturing applications, include ( arranged alphabetically ) ÄKTA ready XL sensor technology (Cytiva Life Sciences), Allegro™ MVP Single-Use System (Pall Corporation) and FUTURA pico (Aber Instruments)...
Read more